Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer
jRCT2031230688Phase 3Active, not recruiting
- Sponsor
- Summit Therapeutics
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Summit Therapeutics. Primary endpoints: Safety assessment, Pharmacokinetics and 2 more. Started May 2024; status: active, not recruiting.
02
Drugs
ivonescimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230688.